Video
Dr. Tward discusses his experience with the Prolaris test for prostate cancer
Author(s):
“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
Video Player is loading.
“I think that getting a really personalized risk estimator can give you a better handle on how much you need to do to achieve the best outcome,” says Jonathan D. Tward, MD, PhD, in discussing the Prolaris test and how his use of the test has evolved over time. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Related Content
